<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Wright, Richard Progress Note</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body><h1 class="h1center">Wright, Richard Progress Note</h1><table class="header_table"><tr><td class="td_header_role_name"><span class="td_label">Patient</span></td><td class="td_header_role_value">Richard W Wright</td></tr><tr><td class="td_header_role_name"><span class="td_label">Date of birth</span></td><td class="td_header_role_value">December 8, 1948 </td></tr><tr><td class="td_header_role_name"><span class="td_label">Current Gender</span></td><td class="td_header_role_value">Male</td></tr><tr><td class="td_header_role_name"><span class="td_label">Race(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>Unknown</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Ethnicity</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>NOT HISPANIC OR LATINO</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Language(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>English</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"> Primary Home Address:<br/>8637 Cremona Dr<br/>Las Vegas, NV 89117<br/><br/>Mobile Phone:  (775)750-5841<br/></td></tr><tr><td class="td_header_role_name"><span class="td_label">Patient IDs</span></td><td class="td_header_role_value">261964 2.16.840.1.113883.3.623<br/></td></tr></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document Id</span></td><td class="td_header_role_value">ProgressNote_Wright_20240826_1536_37.593 2.16.840.1.113883.3.623</td></tr><tr><td class="td_header_role_name"><span class="td_label">Document Created:</span></td><td class="td_header_role_value">August 26, 2024, 15:36:37, MST </td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Ammar Yousif of The Oncology Institute of Hope and Innovation</td></tr><tr><td class="td_header_role_value internal_format"><br/><br/><br/></td></tr></tbody></table></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Author</span></td><td class="td_header_role_value">G2Carequality Interface, The Oncology Institute of Hope and Innovation</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value">Arizona, California, Florida<br/>Downey, CA 90241<br/><br/><br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Encounter Id</span></td><td class="td_header_role_value">9937012 2.16.840.1.113883.19</td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Type</span></td><td class="td_header_role_value">OFFICE/OUTPATIENT ESTABLISHED MOD MDM 30-39 MIN</td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Date</span></td><td class="td_header_role_value"> From September 1, 2023  to September 1, 2023 </td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Location</span></td><td class="td_header_role_value"/></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Informant</span></td><td class="td_header_role_value">Ammar Yousif of The Oncology Institute of Hope and Innovation</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"><br/><br/><br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document maintained by</span></td><td class="td_header_role_value">McKesson Specialty Health</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value">10101 Woodloch Forest<br/>The Woodlands, TX 77380, USA<br/><br/>Work Phone:  800 381 2637<br/></td></tr></tbody></table><h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Assessment</a></li><li><a href="#id2">Allergies and Adverse Reactions</a></li><li><a href="#id3">Plan</a></li><li><a href="#id4">Reason for Visit</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Immunizations</a></li><li><a href="#id7">Diagnostic Results</a></li><li><a href="#id8">Medications</a></li><li><a href="#id9">Problems</a></li><li><a href="#id10">Vital Signs</a></li><li><a href="#id11">Notes Section</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Assessment</a></h3><div>See Clinical Notes section</div><h3><a name="id2" href="#toc">Allergies and Adverse Reactions</a></h3><div><table>
    <thead>
        <tr>
                            <th>Medication/Group Name</th>
                <th>Reaction</th>
                <th>Severity</th>
                <th>Date</th>
        </tr>
    </thead>
    <tbody>
                <tr ID="AlertOBS-1000">
                    <td colspan="4">No known allergies</td>
                </tr>
    </tbody>
</table>
</div><h3><a name="id3" href="#toc">Plan</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="CarePlanRef-1001">
						<td>12/18/2023</td>
						<td>APPOINTMENT</td>
						<td>INJECTIONS</td>
				</tr>
				<tr ID="CarePlanRef-1002">
						<td>09/18/2023</td>
						<td>APPOINTMENT</td>
						<td>INJECTIONS</td>
				</tr>
				<tr ID="CarePlanRef-1003">
						<td>09/01/2023</td>
						<td>APPOINTMENT</td>
						<td>FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1004">
						<td>09/01/2023</td>
						<td>LABORDER</td>
						<td>CBC With Diff and Plt</td>
				</tr>
				<tr ID="CarePlanRef-1005">
						<td>09/01/2023</td>
						<td>LABORDER</td>
						<td>CMP w/ Mag</td>
				</tr>
				<tr ID="CarePlanRef-1006">
						<td>09/01/2023</td>
						<td>LABORDER</td>
						<td>Ferritin</td>
				</tr>
				<tr ID="CarePlanRef-1007">
						<td>09/01/2023</td>
						<td>LABORDER</td>
						<td>Iron, TIBC, %SAT</td>
				</tr>
				<tr ID="CarePlanRef-1008">
						<td>09/01/2023</td>
						<td>LABORDER</td>
						<td>PSA</td>
				</tr>
				<tr ID="CarePlanRef-1009">
						<td>10/26/2023</td>
						<td>LABORDER</td>
						<td>Bone scan, total body</td>
				</tr>
				<tr ID="CarePlanRef-1010">
						<td>10/26/2023</td>
						<td>LABORDER</td>
						<td>CT chest/abdomen/pelvis w/ contrast</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id4" href="#toc">Reason for Visit</a></h3><div>FOLLOW UP</div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="EncounterDiagnosisRef-1011">
							<td>09/01/2023</td>
							<td>Primary malignant neoplasm of prostate (disorder)</td>						
					</tr>
	</tbody>
</table>
</div><h3><a name="id6" href="#toc">Immunizations</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Instructions</th>
				<th>Refusal Reason</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
				<tr><td colspan="7">No data for this encounter</td></tr>
	</tbody>
</table>
</div><h3><a name="id7" href="#toc">Diagnostic Results</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Test</th>
				<th>Units</th>
				<th>Lower Limit</th>
				<th>Upper Limit</th>
				<th>Result</th>
				<th>Flag</th>
				<th>Comments</th>
				<th>Status</th>
				<th>Ordered By</th>
				<th>Specimen Source</th>
				<th>Lab Address</th>
		</tr>
	</thead>
	<tbody>
			<tr><td colspan="13">NONE</td></tr>
	</tbody>
</table>
</div><h3><a name="id8" href="#toc">Medications</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Frequency</th>
				<th>Instructions</th>
				<th>Start Date</th>
				<th>End Date</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="MedicationOBS-1012">
							<td/>
							<td>Leuprolide IM (3 month) </td>
							<td>intramuscularly</td>
							<td>22.5 mg</td>
							<td>every 3 months</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1013">
							<td/>
							<td>Montelukast Oral </td>
							<td>orally</td>
							<td>10.0 mg</td>
							<td>every evening</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1014">
							<td/>
							<td>Albuterol HFA Inhaler 90 mcg/actuation </td>
							<td>inhaled</td>
							<td>1.0 </td>
							<td>4 times per day</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1015">
							<td/>
							<td>Tamsulosin Oral </td>
							<td>orally</td>
							<td>0.4 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1016">
							<td/>
							<td>Zoledronic Acid-Mannitol IV (Reclast) </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1017">
							<td/>
							<td>Atorvastatin Oral </td>
							<td>orally</td>
							<td>20.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1018">
							<td/>
							<td>Losartan Oral </td>
							<td>orally</td>
							<td>25.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1019">
							<td/>
							<td>Bicalutamide Oral </td>
							<td>orally</td>
							<td>50.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1020">
							<td/>
							<td>Baclofen Oral </td>
							<td>orally</td>
							<td>10.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1021">
							<td/>
							<td>Topiramate Oral </td>
							<td>orally</td>
							<td>25.0 mg</td>
							<td>daily</td>
							<td>for 3 days</td>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1022">
							<td/>
							<td>Ascorbic Acid Oral </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1023">
							<td/>
							<td>Docosahexanoic Acid-Eicosapentanoic Acid Oral 120 mg-180 mg </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1024">
							<td/>
							<td>Vitamin B Complex Oral Tablet </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1025">
							<td/>
							<td>Sumatriptan Oral </td>
							<td>orally</td>
							<td>100.0 mg</td>
							<td>every 2 to 4 hours</td>
							<td>prn migraine headache; do not exceed 2 doses per 24 hrs</td>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1026">
							<td/>
							<td>Omeprazole Oral Delayed Release Capsule </td>
							<td>orally</td>
							<td>40.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1027">
							<td/>
							<td>Multivitamins Oral Tablet </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1028">
							<td>04/22/2024</td>
							<td>1.7 ML denosumab 70 MG/ML Injection </td>
							<td>subcutaneously</td>
							<td>120.0 mg</td>
							<td>once</td>
							<td>Administer in upper arm, upper thigh, or abdomen.</td>
							<td>04/22/2024</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1029">
							<td>06/02/2023</td>
							<td>ondansetron 8 MG Disintegrating Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet,disintegrating</td>
							<td>every 8 hours</td>
							<td/>
							<td>06/02/2023</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1030">
							<td>04/26/2023</td>
							<td>bicalutamide 50 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>daily</td>
							<td/>
							<td>04/26/2023</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1031">
							<td>04/17/2023</td>
							<td>bicalutamide 50 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>daily</td>
							<td/>
							<td>04/17/2023</td>
							<td/>
							<td>active</td>
					</tr>
	</tbody>
</table>
</div><h3><a name="id9" href="#toc">Problems</a></h3><div><table>
	<thead>
		<tr>
							<th>Diagnosis</th>
				<th>Status</th>
				<th>Date of Diagnosis</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="ProblemOBS-1032">
						<td>Primary malignant neoplasm of prostate (disorder)</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1033">
						<td>Bone metastasis</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1034">
						<td>Dyslipidemia</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1035">
						<td>History of emphysema (situation)</td>
						<td>Active</td>
						<td/>
				</tr>
	</tbody>
</table>
</div><h3><a name="id10" href="#toc">Vital Signs</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="VitalSignsRef-1036">
						<td>09/01/2023</td>
						<td>
							BMI
							
						</td>
						<td>31.71</td>
				</tr>
				<tr ID="VitalSignsRef-1037">
						<td>09/01/2023</td>
						<td>
							Height
							
						</td>
						<td>70.00</td>
				</tr>
				<tr ID="VitalSignsRef-1038">
						<td>09/01/2023</td>
						<td>
							Weight
							
						</td>
						<td>221.00</td>
				</tr>
				<tr ID="VitalSignsRef-1039">
						<td>09/01/2023</td>
						<td>
							Pain Scale
							
						</td>
						<td>0.00</td>
				</tr>
				<tr ID="VitalSignsRef-1040">
						<td>09/01/2023</td>
						<td>
							BSA
							
						</td>
						<td>2.18</td>
				</tr>
				<tr ID="VitalSignsRef-1041">
						<td>09/01/2023</td>
						<td>
							Oxygen Saturation
							
						</td>
						<td>95.00</td>
				</tr>
				<tr ID="VitalSignsRef-1042">
						<td>09/01/2023</td>
						<td>
							Respiratory Rate
							
						</td>
						<td>20.00</td>
				</tr>
				<tr ID="VitalSignsRef-1043">
						<td>09/01/2023</td>
						<td>
							Heart Beat
							
						</td>
						<td>65.00</td>
				</tr>
				<tr ID="VitalSignsRef-1044">
						<td>09/01/2023</td>
						<td>
							Body Temperature
							
						</td>
						<td>98.70</td>
				</tr>
				<tr ID="VitalSignsRef-1045">
						<td>09/01/2023</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>118</td>
				</tr>
				<tr ID="VitalSignsRef-1046">
						<td>09/01/2023</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>74</td>
				</tr>
				<tr ID="VitalSignsRef-1047">
						<td>09/18/2023</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>127</td>
				</tr>
				<tr ID="VitalSignsRef-1048">
						<td>09/18/2023</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>65</td>
				</tr>
				<tr ID="VitalSignsRef-1049">
						<td>09/18/2023</td>
						<td>
							BSA
							
						</td>
						<td>2.17</td>
				</tr>
				<tr ID="VitalSignsRef-1050">
						<td>09/18/2023</td>
						<td>
							BMI
							
						</td>
						<td>31.54</td>
				</tr>
				<tr ID="VitalSignsRef-1051">
						<td>09/18/2023</td>
						<td>
							Height
							
						</td>
						<td>70.00</td>
				</tr>
				<tr ID="VitalSignsRef-1052">
						<td>09/18/2023</td>
						<td>
							Weight
							
						</td>
						<td>219.80</td>
				</tr>
				<tr ID="VitalSignsRef-1053">
						<td>09/18/2023</td>
						<td>
							Pain Scale
							
						</td>
						<td>0.00</td>
				</tr>
				<tr ID="VitalSignsRef-1054">
						<td>09/18/2023</td>
						<td>
							Oxygen Saturation
							
						</td>
						<td>96.00</td>
				</tr>
				<tr ID="VitalSignsRef-1055">
						<td>09/18/2023</td>
						<td>
							Respiratory Rate
							
						</td>
						<td>16.00</td>
				</tr>
				<tr ID="VitalSignsRef-1056">
						<td>09/18/2023</td>
						<td>
							Heart Beat
							
						</td>
						<td>68.00</td>
				</tr>
				<tr ID="VitalSignsRef-1057">
						<td>12/18/2023</td>
						<td>
							Heart Beat
							
						</td>
						<td>80.00</td>
				</tr>
				<tr ID="VitalSignsRef-1058">
						<td>12/18/2023</td>
						<td>
							Body Temperature
							
						</td>
						<td>98.70</td>
				</tr>
				<tr ID="VitalSignsRef-1059">
						<td>12/18/2023</td>
						<td>
							BMI
							
						</td>
						<td>31.54</td>
				</tr>
				<tr ID="VitalSignsRef-1060">
						<td>12/18/2023</td>
						<td>
							Respiratory Rate
							
						</td>
						<td>20.00</td>
				</tr>
				<tr ID="VitalSignsRef-1061">
						<td>12/18/2023</td>
						<td>
							Oxygen Saturation
							
						</td>
						<td>94.00</td>
				</tr>
				<tr ID="VitalSignsRef-1062">
						<td>12/18/2023</td>
						<td>
							Heart Beat
							
						</td>
						<td>76.00</td>
				</tr>
				<tr ID="VitalSignsRef-1063">
						<td>12/18/2023</td>
						<td>
							BSA
							
						</td>
						<td>2.17</td>
				</tr>
				<tr ID="VitalSignsRef-1064">
						<td>12/18/2023</td>
						<td>
							Pain Scale
							
						</td>
						<td>0.00</td>
				</tr>
				<tr ID="VitalSignsRef-1065">
						<td>12/18/2023</td>
						<td>
							Weight
							
						</td>
						<td>219.80</td>
				</tr>
				<tr ID="VitalSignsRef-1066">
						<td>12/18/2023</td>
						<td>
							Height
							
						</td>
						<td>70.00</td>
				</tr>
				<tr ID="VitalSignsRef-1067">
						<td>12/18/2023</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>128</td>
				</tr>
				<tr ID="VitalSignsRef-1068">
						<td>12/18/2023</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>76</td>
				</tr>
				<tr ID="VitalSignsRef-1069">
						<td>12/18/2023</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>132</td>
				</tr>
				<tr ID="VitalSignsRef-1070">
						<td>12/18/2023</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>82</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id11" href="#toc">Notes Section</a></h3><div>	<ul><li>
		        Follow-Up: 
		        <p>
		        		

<br/>2911 N. Tenaya Way. <br/>Suite 210<br/>Las Vegas, NV  89128

<br/>
<br/>Phone: (702) 342-1244 Fax: (702) 577-2542


<br/>


<br/>Patient Name: Richard Wright

<br/>Date of Birth: 12/08/1948

<br/>Medical Record #: 261964

<br/>Attending Physician: Ammar  Yousif (Hematology/Oncology)

<br/>Location: Las Vegas

<br/>Referring Physician: Lee Winner DO

<br/>


<br/>Follow-Up

<br/>Date of Visit: 09/01/2023

<br/>Reason for Consultation<br/>Prostate- adenocarcinoma Gleason grade 4+5=9, Grade group 5, with bone metastasis 
<br/>

<br/>History of Present Illness

<br/>
<br/>
<br/>This is a 74-year-old gentleman with past medical history of emphysema, chronic back pain, dyslipidemia.  Patient was having urination difficulty underwent TURP on 5/26/2022 pathology revealed prostate cancer Gleason score 4+5 equal 9 group 5 involving approximately 40% of the specimen.  PSA at time of diagnosis was 4.5.  Patient did have staging scans CT chest abdomen pelvis that revealed sclerotic lesion in the lower thoracic and lumbar spine as well as iliac bones.  Bone scan further revealed the sclerotic lesions on June 20, 2022 which showed multiple foci of abnormal uptake in the numerous bones including left scapular clavicle left posterior lateral 11th rib right costovertebral junction, thoracic lumbar spine, sacrum, bilateral iliac bones.  Patient referred initially to radiation oncologist however due to metastatic disease no radiation offered.  Patient referred to Dr. Mehdi at Hope cancer center.  ADT initiated with Casodex and Eligard since July 2022.  Patient reported significant hot flashes tired, fatigue and poor energy since starting ADT therapy.<br/>
<br/>
Interim Hx:<br/>
Patient is here for regular follow up. He reports fatigue, hot flushes and nausea. Denies any change in BM or urination. b/l leg swelling. <br/>
<br/>



<br/>Medical History<br/> <ul><li>Primary malignant neoplasm of prostate (disorder)</li><li>Bone metastasis</li><li>Dyslipidemia</li><li>History of emphysema (situation)</li></ul>

<br/>


<br/>Surgical History<br/>    

<br/>


<br/>Medications<br/> Bicalutamide Oral 50 mg tablet 
1 tablet orally daily. , Topiramate Oral 25 mg orally daily for 3 days, Ondansetron Oral Disintegrating Tablet 8 mg tablet,disintegrating 
1 tablet,disintegrating orally every 8 hours as needed for nausea and vomiting. , Fish Oil (Docosahexanoic Acid-Eicosapentanoic Acid Oral 120 mg-180 mg), Sumatriptan Oral 100 mg orally every 2 to 4 hours prn migraine headache; do not exceed 2 doses per 24 hrs, Omeprazole Oral Delayed Release Capsule 40 mg orally daily, Tamsulosin Oral 0.4 mg orally daily, Losartan Oral 25 mg orally daily, Albuterol HFA Inhaler 90 mcg/actuation inhaled 4 times per day, B Complex-Vitamin B12 (Vitamin B Complex Oral Tablet), Baclofen Oral 10 mg orally daily, Multivitamins Oral Tablet, Zoledronic Acid-Mannitol IV (Reclast), Atorvastatin Oral 20 mg orally daily, Bicalutamide Oral 50 mg orally daily, Leuprolide IM (3 month) 22.5 mg intramuscularly every 3 months, Vitamin C (Ascorbic Acid Oral), Montelukast Oral 10 mg orally every evening

<br/>


<br/>    

<br/>


<br/>Smoking History<br/>


<br/>Smoking Tobacco : Former smoker, pack years: 25, started smoking: 1956, stopped smoking: 1981; Smokeless Tobacco : none found; Vaping : none found

<br/>


<br/>Social History

<br/>
<br/>
<br/>
<br/>Alcohol Use: Stopped drinking in 1985

<br/>Recreational Drug Use: Stopped marijuana in 1975

<br/>Marital Status: Married

<br/>Children: 0




<br/>Family History<br/> <ul><li>Father: Deceased - Brain/CNS cancer</li><li>Mother: Deceased - Lung cancer</li></ul>

<br/>


<br/>Allergies<br/> No known medication allergies

<br/>


<br/>Review of Systems

<br/>Constitutional: Denies fever, weight loss, fatigue<br/>Eyes: Denies visual changes<br/>ENT/Mouth: Denies hearing problems, oral problems<br/>Cardiovascular: Denies chest pain, palpitations<br/>Respiratory: Denies shortness of breath, cough<br/>Gastrointestinal: Denies abdominal pain, nausea, vomiting, constipation, diarrhea<br/>Genitourinary: Denies burning, pain on urination, blood in urine, incontinence<br/>Musculoskeletal: Denies muscle pain, bone pain, joint pain<br/>Skin: Denies rashes, itchiness, ulcers<br/>Neurologic: Denies headaches, dizziness, confusion, seizures, weakness or numbness<br/>Psychiatric: Denies depression, anxiety<br/>Hematologic/Lymphatic: Denies other bleeding, bruising, swollen lymph nodes

<br/>


<br/>Physical Examination

<br/>Blood pressure: 118/74, Sitting, R arm, Regular, Pulse: 65, Temperature: 98.7 F, Respirations: 20, O2 sat: 95%, At Rest, Room Air, Pain Scale: 0, Height: 70 in, Weight: 221 lb, BSA: 2.18, BMI: 31.71 kg/m2

<br/>


<br/>General:  Alert &amp; oriented, no acute distress<br/>Skin: Normal<br/>HEENT:  Pupils equal, round. Oral cavity, oropharynx clear<br/>Neck:  Supple, no mass<br/>Breast: Deferred<br/>Lungs: Clear to auscultation, bilaterally<br/>Heart: Regular rate and rhythm, no murmurs, rubs or gallops<br/>Back: Nontender<br/>Abdomen: Soft, nontender, nondistended, no masses palpable, no hepatosplenomegaly, normal bowel sounds<br/>Genitourinary: Deferred<br/>Extremities: No clubbing, cyanosis, or edema<br/>


<br/>Laboratory<br/>
<br/>CBC<br/>(08/24/2023) WBC x 10^3/uL : 5.1; RBC x 10^6/uL : 3.84 (L); HGB g/dL : 12.8 (L); HCT % : 37.5 (L); MCV fL : 97.7; MCH pg : 33.3 (H); MCHC g/dL : 34.1; RDW % : 12.4; PLT x 10^3/uL : 245; MPV fL : 9.4; Neu % : 55.9; LY % : 26.4; MO % : 11.6; EO % : 5.3; BA % : 0.8; NEU #, cells/uL : 2851; LY #, cells/uL : 1346; MO #, cells/uL : 592; EO #, cells/uL : 270; BA #, cells/uL : 41

<br/>
<br/>Manual Differential<br/>(08/24/2023) NRBC, #/100 wbc : DNR; NRBC, absolute, cells/uL (M) cells/uL : DNR; Band % : DNR; Promyelocyte % : DNR; Bands, absolute, cells/uL : DNR; Promyelocyte, absolute, cells/uL : DNR

<br/>CMP<br/>(08/24/2023) Glucose mg/dL : 87; BUN mg/dL : 15; Creatinine mg/dL : 0.92; BUN/Creatinine ratio : SEE NOTE:; Sodium mmol/L : 139; Potassium mmol/L : 4.2; Chloride mmol/L : 103; CO2 mmol/L : 29; Calcium mg/dL : 9.6; Albumin g/dL : 4.2; Total protein g/dL : 6.6; Globulin g/dL : 2.4; A/G ratio : 1.8; Bilirubin, total mg/dL : 0.4; Alkaline phosphatase U/L : 65; AST/SGOT U/L : 19; ALT/SGPT U/L : 20<br/>(03/16/2023) Magnesium, mg/dL : 2.2; Vitamin D, 25-hydroxy ng/mL : 43

<br/>Tumor Markers<br/>(08/24/2023) PSA ng/mL : 0.17

<br/>Anemia Labs<br/>(08/24/2023) Iron / FE ug/dL : 166; TIBC ug/dL : 288; Ferritin ng/mL : 186

<br/>

<br/>

<br/>Hormones<br/>(05/17/2023) Testosterone, total ng/dL : 12 (L); Triiodothyronine (T3) ng/dL : 127<br/>(03/16/2023) TSH, mIU/L : 1.64

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>Other<br/>(08/24/2023) CBC Comments : DNR; EGFR : 87; ABSOLUTE BLASTS : DNR; ABSOLUTE METAMYELOCYTES : DNR; ABSOLUTE MYELOCYTES : DNR; BLASTS : DNR; METAMYELOCYTES : DNR; MYELOCYTES : DNR; REACTIVE LYMPHOCYTES : DNR; % SATURATION : 58 (H); Clinical PDF Report EN406296Y-1 : See attached<br/>(05/17/2023) ABN TEST REFUSED : 622,866,867,899,17306; RAM : See notes<br/>(03/16/2023) Enhanced PDF Report ZL908869B-1 : See attached


<br/>



<br/>Radiology<br/>
<br/>


<br/>Pathology<br/> <br/>

<br/>Impression and Recommendations

<br/>
<br/>
<br/>#Prostate- adenocarcinoma Gleason grade 4+5=9, Grade group 5, with bone metastasis <br/>
#Bone metastasis <br/>
#COPD/Emphysema <br/>
#Dyslipedemia <br/>
#Remote history of left kidney nephrectomy <br/>
<br/>
-TURP on 5/26/2022 pathology revealed prostate cancer Gleason score 4+5 equal 9 group 5 involving approximately 40% of the specimen.  -PSA at time of diagnosis was 4.5.  <br/>
-Staging scans CT chest abdomen pelvis that revealed sclerotic lesion in the lower thoracic and lumbar spine as well as iliac bones.  <br/>
-Bone scan further revealed the sclerotic lesions on June 20, 2022 which showed multiple foci of abnormal uptake in the numerous bones including left scapular clavicle left posterior lateral 11th rib right costovertebral junction, thoracic lumbar spine, sacrum, bilateral iliac bones.<br/>
-ADT initiated with Casodex and Eligard since July 2022. <br/>
-Bone scan 12/20/2022: Decreased uptake within osseous metastatic disease, suggestive of response to therapy. No definite new areas of osseous metastatic disease are demonstrated.<br/>
-Bone scan and CT C/A/P 5/18/2023: Stable osseous metastatic disease. No evidence of new or progressing osseous metastatic disease. Stable osseous metastatic disease. No evidence of new or progressing osseous metastatic disease.<br/>
<br/>
Plan:<br/>
-Eligard 22.5mg Q3 months, due 09/19/23 <br/>
-Zometa Q3 months, will space it out, give it 1 month after Eligard to assess toxicity , scheduled 10/18/2023 <br/>
-Xtandi, prescription sent but patient declined <br/>
-RTC 01/16/2024 with repeated labs <br/>
<br/>



<br/>Discussion

<br/>


<br/>
<br/>ECOG: N/A


<br/>Depression: N/A

<br/>


<br/>Diagnosis<br/>


<br/><ul><li>Primary malignant neoplasm of prostate (disorder) ( Stage Date: 05/26/2022, Stage IVB (TX, N0, cM1b, &lt; 10, 5)-Clinical )</li></ul>

<br/>CC<br/>    

<br/>


<br/>Signature<br/>
<br/>


<br/>Note created by Ammar Yousif MD, Physician, Hematology/Oncology
<br/>Electronically signed by Ammar Yousif MD 09/01/2023 12:31 PM PDT 
		        </p>
		      </li><li>
		        Nurse Note for: 18-DEC-23: 
		        <p>
		        		The Oncology Institute of Hope and Innovation<br/>Nurse Note<br/>Print Location: Unknown<br/>Date/Time Printed: 08/26/2024 03:36 PM (America/Los_Angeles)<br/>Patient: Wright, Richard W     Sex: Male      DOB: 12/08/1948      MRN:  261964<br/>Date of Service: 12/18/2023<br/>Allergies :<br/>No Known Allergies<br/>Vital Signs :<br/>Time: 11:16 AM. Weight: 219.8 lb (99.70 kg). Height: 70 in (177.80 cm). BMI: 31.54 (kg/m2) . BSA: 2.17 (m2) . Temperature: 98.7 F (37.06 C) forehead. Pulse: 76 (/min)  radial sitting. Respirations: 20 (/min) . Blood pressure: 128/76 (mm Hg) right arm Regular. Pain Scale: 0. O2 Saturation: 94 (%)  at rest.  Entered by Jenny Hulsey MA 12/18/2023 11:17 AM<br/>Incident To Details :<br/>Incident to physician is present and immediately available to furnish assistance and provide supervision throughout the treatment.<br/>Entered By Junna Ota RN on 12:36 PM<br/>Patient Assessment :<br/>Negative results Assessment :<br/>Denies Pain -0-No pain. <br/>Entered By Junna Ota RN on 12:36 PM<br/>IV Access/Lab Draw :<br/>IV Access-Peripheral - New Start, Needle Type-Iv Cath, Needle Size-24 Gauge, Access Site-Right Hand, Flush-10ml NS, Site Assess List-Blood Return,No Redness,No Swelling,No Tenderness,No Bruising, Site Care Checklist-Aseptic Technique, Dressing Change-Tegaderm,Alcohol, <br/>Entered By Junna Ota RN on 12:35 PM<br/>IV De-Access :<br/>IV Access Method-Peripheral - New Start, IV Access Type-Iv Cath, Line Flushed-10ml NS, Catheter-Dc'd, Site Care-Site Dressing Applied,Dressing left intact,IV Infusion Completed,Blood Return Noted During Administration,Therapy Completed Without Adverse Event,Occlusive Dressing Applied, Site Assess-Line Intact,No Redness,No Swelling,No Tenderness,No Bruising, <br/>Entered By Junna Ota RN on 12:35 PM<br/>Discharge Note :<br/>Comments-Therapy completed without adverse event, Catheter removed intact, Dressing intact, Discharged from clinic, Stable, No new complaints, Plan for next patient visit confirmed, Patient instructed to call office with any questions or problems, Accompanied By-Self, Discharge-Ambulatory<br/>Entered By Junna Ota RN on 12:36 PM<br/>Medication Administration :<br/>Incident to: Yousif, Ammar, MD<br/>TOI- Eligard<br/>Hormone Therapy<br/>Eligard (Leuprolide Subcutaneous (3 month)), 22.5 mg syringe, 22.5 mg subcutaneously every 3 months, Allow Substitution<br/>     GIVEN: 22.5 mg<br/>     Pharmacy plan: Dose Form Description: 22.5 mg syringe Dispense/Waste: 22.5/0 mg<br/>     Pharmacy dispense: NDC: 62935022305 Dispense/Waste: 22.5/0 mg<br/>     Given Dose/Discard: 22.5/0 mg<br/>     Admin Details: Injection Location: Left-Dorsogluteal<br/>     Time: 11:16 AM<br/> 
		        </p>
		      </li><li>
		        Nurse Note for: 18-SEP-23: 
		        <p>
		        		The Oncology Institute of Hope and Innovation<br/>Nurse Note<br/>Print Location: Unknown<br/>Date/Time Printed: 08/26/2024 03:36 PM (America/Los_Angeles)<br/>Patient: Wright, Richard W     Sex: Male      DOB: 12/08/1948      MRN:  261964<br/>Date of Service: 09/18/2023<br/>Allergies :<br/>No Known Allergies<br/>Vital Signs :<br/>Time: 10:03 AM. Weight: 219.8 lb (99.70 kg). Height: 70 in (177.80 cm). BMI: 31.54 (kg/m2) . BSA: 2.17 (m2) . Pulse: 68 (/min) . Respirations: 16 (/min) . Blood pressure: 127/65 (mm Hg) right arm. Pain Scale: 0. O2 Saturation: 96 (%)  at rest.  Entered by Genesis Rojas MA 09/18/2023 10:03 AM<br/>Patient Assessment :<br/>Negative results Assessment :<br/>Denies Pain -0-No pain. <br/>Medication Administration :<br/>Incident to: Yousif, Ammar, MD<br/>TOI- Eligard<br/>Hormone Therapy<br/>Eligard (Leuprolide Subcutaneous (3 month)), 22.5 mg syringe, 22.5 mg subcutaneously every 3 months, Allow Substitution<br/>     GIVEN: 22.5 mg<br/>     Pharmacy plan: Dose Form Description: 22.5 mg syringe Dispense/Waste: 22.5/0 mg<br/>     Pharmacy dispense: NDC: 62935022305 Dispense/Waste: 22.5/0 mg<br/>     Given Dose/Discard: 22.5/0 mg<br/>     Admin Details: Injection Location: Right-Upper Arm<br/>     Time: 10:10 AM<br/> 
		        </p>
		      </li></ul>
</div><br/><br/></body></html>